Previous 10 | Next 10 |
YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and busine...
Introduction The share price of OptiNose ( OPTN ) has not been performing well in 2020. Investors seemed to have lost confidence in the company and shares have suffered again after the company initiated an additional equity offering in mid-August. This might be short-sighted without having t...
Sunnova Energy International (NYSE: NOVA) . Rimini Street (NASDAQ: RMNI) . OptiNose (NASDAQ: OPTN) . What do a solar panel installer; a database software contractor; and a pharmaceutical company specializing in ear, nose, and throat treatments have in common? They're all stocks su...
Gainers: Midatech Pharma (NASDAQ: MTP ) +59% . More news on: Midatech Pharma plc, Mesoblast Limited, Sky Solar Holdings, Ltd., Stocks on the move, , Read more ...
Hexindai (NASDAQ: HX ) -41% . More news on: Hexindai Inc., Usio, Inc., Biofrontera AG, Stocks on the move, , Read more ...
Optinose (NASDAQ: OPTN ) prices its public offering of 6M common shares at $5.85 per share. Underwriters' over-allotment is an additional 900K shares. Closing date is August 18. More news on: OptiNose, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
OptiNose, Inc. (OPTN) Q2 2020 Earnings Conference Call August 4, 2020 08:00 ET Company Participants Jonathan Neely - Vice President, Investor Relations Peter Miller - Chief Executive Officer Ramy Mahmoud - President and Chief Operating Officer Vic Clavelli - Chief Commercial Of...
Image source: The Motley Fool. OptiNose, Inc. (NASDAQ: OPTN) Q2 2020 Earnings Call Aug 4, 2020 , 8:00 a.m. ET Operator Continue reading
Company reports second quarter 2020 XHANCE net revenue of $10.3 million Second quarter 2020 XHANCE prescriptions increased 84% from second quarter 2019 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Optin...
YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2020 and corporate updates...
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...